PowerPoint 프레젠테이션

Similar documents
<30322E535453BABBB9AE2DC6EDC1FD2E687770>

<30322E535453BABBB9AE2DC6EDC1FD2E687770>

211 년대한임상건강증진학회춘계통합학술대회 치료대상 치료대상 만성 B 형간염 간경변증 HBeAg (+) HBeAg (-) Compensated Decompensated KASL (27) 2 x UNL 2, 2 x UNL 2, APASL (28) 2 x UNL 2, 2

ePapyrus PDF Document

Microsoft PowerPoint - Young Seok Kim.pptx

<303320C6AFC1FD C0CCC7FDBFF82DBEC8BBF3C8C62E687770>

2018- PG Course편집.hwp

KOL Slidekit (Sep 2005)

<30352EC0CCBFACC0E72E687770>

PowerPoint 프레젠테이션

C형 간염 치료 부작용 관리

정재연 B 형간염치료약제의보험급여현황 양급여를인정받을것으로예상된다. 이중라미부딘은 2012년 9월 1일부터라미부딘제제보다높은유전적장벽 (genetic barrier) 이있는다른항바이러스제를사용할수없거나적절하지않은경우에한하며, 투여소견서를첨부하여야급여를인정받을수있게되었다

untitled

00약제부봄호c03逞풚

<30322EBABBB9AE2E687770>

untitled

<C0D3BBF3B0C7B0ADC1F5C1F8C7D0C8B C3DFB0E8C7D0BCFAB4EBC8B82DBFACBCF6B0ADC1C22E687770>

Microsoft PowerPoint - CNVZNGWAIYSE.pptx

<30322E535453BABBB9AE2DC6EDC1FD2E687770>

Epidemiol Health 217;39:e21717 서론 C형간염바이러스 (hepatitis C virus, HCV) 는 5 nm 크기의외피를가진 RNA 바이러스로 Flaviviridae family에속하며 1989 년에그존재가처음밝혀졌다. 주로 C형간염선별검사이전

기관고유연구사업결과보고

김범수

( )Jkstro011.hwp

C 형간염치료제의개발현황 김명화 1. 질환개요 C형간바이러스 (Hepatitis C virus, HCV) 는급, 만성간염, 간경변증및간세포암종의주요원인중하나이다. HCV는혈액을통해우리몸속으로들어온뒤간세포내에서주로존재하게되는데이때 C형간염바이러스를제거하기위한면역반응으로인

2018- PG Course편집.hwp

<BABBB9AE2E687770>

04. Review - in-depth review.hwp

Çмúº¸°í7¹ÚÀ¯°æ

<30392EBCADB0E6BCAE2E687770>

Microsoft PowerPoint Free Papers (Abstracts)12.ppt

슬라이드 1

Çмú°�ÁÂÃÖÀº¿µ

Minimally invasive parathyroidectomy


< C0D3BBF3B0C7B0AD20C3E1B0E8C7D0BCFAB4EBC8B82DBFACBCF6B0ADC1C22E687770>

Treatment and Role of Hormaonal Replaement Therapy

<30332E B4EBC7D1B0A1C1A4C0C7C7D0C8B820BCADBFEFC1F6C8B820C3E1B0E82DC3D6C1BE2E687770>


untitled

( )Kju269.hwp

A 617

19차 간학회 추계학술대회_표지.indd

요약문 ( 한글 )

< B5BFBEC6BDC3BEC6BBE E687770>

歯 조선일보.PDF

[ 문서제목 ] ㅍ 세상에서가장비싼알약 만성 C 형간염치료제 소발디 와 하보니 저자최병철 약학정보원학술자문위원 머리말 2013 년 12 월미 FDA 는길리어드사이언스 (Gilead Sciences) 의소발디 (Sovaldi) 와하보니 (Harvoni) 를만성 C 형바이

Kjcg007( ).hwp

May 10~ Hotel Inter-Burgo Exco, Daegu Plenary lectures From metabolic syndrome to diabetes Meta-inflammation responsible for the progression fr

Current update on immunization in cirrhosis

제 21 차대한간학회추계학술대회 연구는대부분라미부딘경험이있거나복합요법을하는경우가많아다약제내성이상당수포함되며아 데포비어내성인 A181T/V 는라미부딘에도내성을가지고엔테카비어는그자체로다약제내성이므로본 고에서는내성치료의변천과각약제의내성에대한연구결과에대해정리해보고자한다. 본론

Pharmacotherapeutics Application of New Pathogenesis on the Drug Treatment of Diabetes Young Seol Kim, M.D. Department of Endocrinology Kyung Hee Univ


<B0A3C3DFB0E828C0DBBEF7292E687770>

<30382EC0C7C7D0B0ADC1C22E687770>

전립선암발생률추정과관련요인분석 : The Korean Cancer Prevention Study-II (KCPS-II)

15강 판소리계 소설 심청전 다음 글을 읽고 물음에 답하시오. [1106월 평가원] 1)심청이 수궁에 머물 적에 옥황상제의 명이니 거행이 오죽 하랴. 2) 사해 용왕이 다 각기 시녀를 보내어 아침저녁으로 문 안하고, 번갈아 당번을 서서 문안하고 호위하며, 금수능라 비

untitled

황지웅

원위부요척골관절질환에서의초음파 유도하스테로이드주사치료의효과 - 후향적 1 년경과관찰연구 - 연세대학교대학원 의학과 남상현

°Ç°�°úÁúº´6-2È£

<43C7FCB0A3BFB020C1F8B7E1B0A1C0CCB5E5B6F3C0CE2E687770>


간질환 환자에서의 수술 위험도 평가 및 흔히 접하는 타과 협진 의뢰

레이아웃 1

ƯÁý1±èâ¿í

(Microsoft PowerPoint - S13-3_\261\350\273\363\307\366 [\310\243\310\257 \270\360\265\345])

내지4월최종


며 오스본을 중심으로 한 작은 정부, 시장 개혁정책을 밀고 나갔다. 이에 대응 하여 노동당은 보수당과 극명히 반대되는 정강 정책을 내세웠다. 영국의 정치 상황은 새누리당과 더불어 민주당, 국민의당이 서로 경제 민주화 와 무차별적 복지공약을 앞세우며 표를 구걸하기 위한


단위: 환경정책 형산강살리기 수중정화활동 지원 10,000,000원*90%<절감> 형산강살리기 환경정화 및 감시활동 5,000,000원*90%<절감> 9,000 4, 민간행사보조 9,000 10,000 1,000 자연보호기념식 및 백일장(사생,서예)대회 10

(SD)신작영화 (SD)신작영화 뽀로로극장판-슈퍼썰매대모험 ,000 (SD)신작영화 (SD)신작영화 콜럼버스서클 ,000 (SD)신작영화 (SD)신작영화 세인츠앤솔저-공수특전대 2013.

(Microsoft PowerPoint - CXBTUEOAPVQY.ppt [\310\243\310\257 \270\360\265\345])

590호(01-11)

< C1DFB5EE31C2F72DB1B9BEEE2DC0FCB0F8422E687770>

2005년 6월 고1 전국연합학력평가

untitled

伐)이라고 하였는데, 라자(羅字)는 나자(那字)로 쓰기도 하고 야자(耶字)로 쓰기도 한다. 또 서벌(徐伐)이라고도 한다. 세속에서 경자(京字)를 새겨 서벌(徐伐)이라고 한다. 이 때문에 또 사라(斯羅)라고 하기도 하고, 또 사로(斯盧)라고 하기도 한다. 재위 기간은 6

0429bodo.hwp

時 習 說 ) 5), 원호설( 元 昊 說 ) 6) 등이 있다. 7) 이 가운데 임제설에 동의하는바, 상세한 논의는 황패강의 논의로 미루나 그의 논의에 논거로서 빠져 있는 부분을 보강하여 임제설에 대한 변증( 辨 證 )을 덧붙이고자 한다. 우선, 다음의 인용문을 보도록

cls46-06(심우영).hwp

최우석.hwp

교사용지도서_쓰기.hwp

< BDC3BAB8C1A4B1D4C6C75BC8A3BFDC D2E687770>

E1-정답및풀이(1~24)ok

<C1B6BCB1B4EBBCBCBDC3B1E2342DC3D6C1BE2E687770>


<C0CEBCE2BABB2D33C2F7BCF6C1A420B1B9BFAAC3D1BCAD203130B1C72E687770>

untitled

민주장정-노동운동(분권).indd

과 위 가 오는 경우에는 앞말 받침을 대표음으로 바꾼 [다가페]와 [흐귀 에]가 올바른 발음이 [안자서], [할튼], [업쓰므로], [절믐] 풀이 자음으로 끝나는 말인 앉- 과 핥-, 없-, 젊- 에 각각 모음으로 시작하는 형식형태소인 -아서, -은, -으므로, -음

6±Ç¸ñÂ÷

<C3D6C1BE5FBBF5B1B9BEEEBBFDC8B0B0DCBFEFC8A C3D6C1BEBABB292E687770>

초등국어에서 관용표현 지도 방안 연구

177

제주어 교육자료(중등)-작업.hwp

¸é¸ñ¼Ò½ÄÁö 63È£_³»Áö ÃÖÁ¾

01Report_210-4.hwp

<C3D1BCB15FC0CCC8C45FBFECB8AE5FB1B3C0B0C0C75FB9E6C7E D352D32315FC5E4292E687770>


Transcription:

Optimal Treatment of HCV in Various Situations 전남의대소화기내과 최성규

내용 급성 C형간염의치료 간경변증환자의치료 간이식후치료 콩팥병환자의치료 HIV 중복감염 HBV 중복감염 정맥주사약물남용자 노년환자의치료 2013 KASL C형간염진료가이드라인페그인터페론알파 / 리바비린 2014 EASL guideline PI (TVR, BOC) based triple therapy 2014 AASLD guideline Sofosbuvir based therapy 2014 EASL postgraduate course & abstracts

급성 C 형간염의치료 진단 : anti-hcv(-)/hcv RNA(+), LFT 상승 치료시작 : 8-12주경과관찰후 치료기간 : 24주 치료제 : 페그인터페론알파단독 실패한경우 : PEG-IFN/RBV, PI based triple therapy (G1)

A: 55명증상 + 바로 PegIFN 24주 B: 52명증상 + 12주후 HCV RNA(+) (22명) PegIFN/RBV 24주 HCV RNA(-) (20명) 4명 HCV RNA + C: 25명무증상 + 바로 PegIFN 24주 Genotype 1 : 66% Delayed treatment is effective although not of equal efficacy to immediate treatment. Deterding K, et al. Lancet Infect Dis 2013;13:497

8-12 주관찰기간 PEG-IFNα-2b (1.5 ug/kg) 8 주 (34 명 ), 12 주 (34 명 ), 24 주 (34 명 ) Duration of Treatment genotype RVR Kamal SM, et al. Hepatology 2006;43:923

만성 B 형간염치료종료후의예후 44 명 43 명 43 명 Response rate combination therapy duration Santantonio T, et al. Hepatology. 2014

대상성간경변환자의치료 적극적인항바이러스치료 - 철저한감시와대비 PEG-IFNα + RBV : 국내 SVR 률 1 형 : 20.8%, 2 형 : 52.6% 혈액학적부작용 : recombinant erythropoietin, G-CSF PI based triple therapy (telaprevir, boceprevir) SVR 증가 (naïve & treatment experienced G1) response guided therapy보다 48주치료 serious adverse events (platelet <100,000/mm 3, albumin<3.5 g/dl) Treatment- naïve patients with compensated cirrhosis (HCC) - same treatment without cirrhosis (IA, AASLD) (sofosbuvir based therapy) SVR 도달 간경변합병증및간세포암종발생감시

PI based triple therapy in GT1 cirrhosis Naïve patients OPIMIZE trial (phase 3) TVR (bid, tid) SVR12 : 51% (77% š cirrhosis) RVR 있으면 24주투여 : SVR 67.9% (86.3% š cirrhosis) SPRINT-2 (phase 3) - 4 weeks PEGIFN/RBV + BOC SVR : F4-42% (F0-F2 : 67%) CUPIC study (treatment experienced cirrhotic patients) Telaprevir Boceprevir Relapsers 74.2% 53.9% Partial responders 40% 38.3% Null responders 19.4% 0% Hezode C. 2014 EASL PG course

Risk of severe complications and SVR12 in treatment experienced patients with compensated cirrhosis Platelet count 100,000/mm 3 Platelet count >100,000/mm 3 Albumin <35 g/l N Complications, n(%) 37 19(51.4%) 31 5(16.1%) SVR12, n(%) 10(27.0%) 9(29%) Albumin 35 g/l N Complications, n(%) 74 9(12.2%) 306 19(6.2%) SVR12, n(%) 27(38.5%) 168(54.9%) Severe adverse events : 49.9% (10.4% decompensation or severe infection, 2.2% death) Hezode C. 2014 EASL PG course

NEUTRINO trial (phase 3) Sofosbuvir 400 mg/d + PEG(2a) 180 ug/week + weight based RBV (1000-1200 mg) for 12 weeks (291 treatment naïve patients with genotype 1) SVR12 : 89% (cirrhosis : 80%, without cirrhosis : 92%) COSMOS (phase 2, genotype 1) SOF 400 mg/d + simeprevir 150 mg/d ± RBV for 12 or 24 weeks Cohort 1 : null responder to PEG/RBV (F0-2) SVR12 12 wks : 96%(26/27), 93% (š RBV, 13/14) 24 wks : 91%(19/21), 100% (š RBV, 13/13) Cohort 2 : naive or null responder (F3-4) SVR4 : naïve : 100%(12/12), 100%(7/7) (š RBV) null : 93%(14/15), 100% (7/7) (š RBV)

AASLD guideline (initial treatment & relapsers) GT Recommended 1 IFN eligible : SOF + PEG/RBV x 12 weeks IFN ineligible : SOF + SMV ± RBV x 12 weeks Alternative SMV 12 weeks + PEG/RBV x 24 weeks SOF + RBV x 24 weeks 2 SOF + RBV x 12 weeks none 3 SOF + RBV x 24 weeks SOF + PEG/RBV x 12 weeks 4 IFN eligible : SOF + PEG/RBV x 12 weeks IFN ineligible : SOF + RBV x 24 weeks SMV 12 wks + PEG/RBV x 24-48 weeks 5-6 SOF + PEG/RBV x 12 weeks PEG/RBV x 48 weeks Not recommended G1 : TVR or BOC + PEG/RBV x 24 or 48 weeks (RGT), PEG/RBV x 48 weeks Monotherapy with PEG, RBV, or a DAA Do not treat decompensated cirrhosis with PEG or SMV G2, 3 : PEG/RBV x 24 weeks, G3 (24-48 weeks) Monotherapy with PEG, RBV, or a DAA, Any regimen with TVR, BOC, or SMV G4 : PEG/RBV 48 weeks Monotherapy with PEG, RBV, or a DAA, Any regimen with TVR, BOC

비대상성간경변환자의치료 비대상성간경변 (CTP B) : 경험이많은센터 페그인터페론알파 + 리바비린국내소규모성적 (10명, 유전자형 1형 8명 ) : SVR 20.0% 표준용량- 용량감소, 투약중단 (>50%) 저용량부터시작하여 2주마다증량 (Peg-INFα-2a 90 ug/wk, 2b 0.5 ug/kg/wk + 리바비린 600 mg/d) 비대상성간경변 (CTP C) : 병합요법을권고하지않는다. Decompensated cirrhosis (CTP B or C) Refer to expertised practitioner (LT center) (IC) Sofosbuvir (400 mg/d) + wt based RBV (creatinine clearance, Hb) for up to 48 weeks (IIb B, AASLD) Not recommend Any IFN based therapy (III A) Monotherapy with PEG, RBV, or a DAA (III A) Telaprevir, boceprevir, or simeprevir- based therapy (III A)

SOF+ RBV for up to 48 weeks 61 patients : HCV and HCC (within MILAN criteria) median MELD : 8 (6-14), CTP 7-8 (class B) 44 patients LT : 41 patients (93%) HCVRNA below LLOQ post-lt 12 weeks : 23/37 (62%) HCVRNA(-) AE : fatigue, anemia, headache Treatment discontinuation : 2 patients (3%) Curry MP, et al. 64 th Annual Meeting of AASLD, 2013 SOB +RBV for 48 weeks : cirrhosis (25 Tx, 25 observation) CTP 5-6 40%, CTP 7-10 60% RVR4 : 89%, RVR8 : 97% 1- nonresponder 3- discontinue (1 AE) AE- nausea, fatigue, dizziness Afdhal N, et al. 49 th Annual Meeting of EASL, 2014

Sofosbuvir/Ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations G3 naive G3 naive G1 CTP B G1 prior SOF SOF/LDV SOF/LDV+RBV SOF/LDV SOF/LDV+RBV 12 wk (n=25) 12 wk (n=26) 12 wk (n=20) 12 wk (n=19) RVR 23/25(92%) 23/26(88%) 15/20(75%) 19/19(100%) ETVR 23/25(92%) 26/26(100%) 20/20(100%) 17/17(100%) SVR4 17/25(68%) 26/26(100%) 16/18(89%) 14/14(100%) SVR12 16/25(64%) 26/26(100%) Pending Pending Gane EJ, et al. 49 th Annual Meeting of EASL, 2014

MK-5172 and MK-8742 ± Ribavirin in HCV G1 patients with cirrhosis or previous null-response. C-WORTHY STUDY MK-5172 : NS3/4A protease inhibitor MK-8742 : NS5A replication complex inhibitor MK-5172 100mg QD + MK8742 50mg QD ± wt based RBG for 12-18 weeks Treatment response <25 IU/mL Cirrhosis Population TW2 (n=254) TW4 (n=245) MK5172/MK8742+RBV Yes Naive 70%(45/64) 97%(56/58) MK5172/MK8742 Yes Naïve 73%(45/61) 95%(58/61) MK5172/MK8742+RBV Yes Null-responder 68%(19/28) 100%(27/27) MK5172/MK8742 Yes Null-responder 59%(17/29) 97%(28/29) MK5172/MK8742+RBV No Null-responder 66%(23/35) 97%(33/34) MK5172/MK8742 No Null-responder 72%(27/37) 94%(34/36) Lawitz E, et al. 49 th Annual Meeting of EASL, 2014

Compensated cirrhosis Child-Pugh <8 (MELD<18) Genotypes 2, 3 Patients awaiting LT (HCV) Genotypes 1,4 Decompensated cirrhosis Child-Pugh 8 (MELD 18) Current therapy PEG-IFN+RBV SOF+RBV PEG-IFN+RBV (±TVR/BOC in G1) SOF +PEG/RBV SOF+SMV±RBV SMV +PEG/RBV Incoming therapy No treatment SOF + RBV ABT-450/r+ABT-267+ABT-333+RBV Asunaprevir + Daclatasvir MK-5172+ MK-8742 ± RBV Sofosbuvir + Ledipasvir (±RBV) Sofosbuvir + Simeprevir (±RBV) Sofosbuvir + Daclatasvir (±RBV) Marino Z, et al 2014 EASL, PG course

간이식후치료 치료시작 after confirmed histological damage ( 이식후 6개월이상경과 ) significant fibrosis (F 2), portal hypertension (HVPG 6 mmhg) fibrosing cholestatic hepatitis 치료요법 PEG-IFN + RBV : SVR 30-40% discontiuation (20-38%), dose reduction (66-73%), poor tolerance, risk of rejection ~5% PI based triple therapy (TVR, BOC in G1) - SVR12 : 48-59% discontiuation (13-26%), anemia drug interaction dose adjustments of CyS, TAC IFN-free regimens : SOF, SMV, RBV

IFN-free regimen- Sofosbuvir based 40 patients recurrent HCV infection following LT (6 months) MELD 17, CTP 7 65%(25/40) bridging fibrosis, cirrhosis SOF 400 mg/d + RBV (600 mg/d escalating) x 24 weeks End of treatment : 100% HCVRNA (< LLOQ) SVR4 : 77% (27/35) AE : fatigue, headache, athralgia, anemia(20%) Charlton MR, et al 64 th Annual Meeting of AASLD, 2013 Sofosbuvir compassionate-use program - severe recurrent HCV infection following LT 57 SOF+RBV, 30 SOF+RBV+PEG up to 48 weeks SVR12 : 54% (SOF+RBV) 44% (SOF+RBV+PEG) 76명중 53명 (70%) - improved on Tx, 10명 (13%) stable liver disease 13명 (17%) death progression of liver disease 33% AE Forns X, et al 49 th Annual Meeting of EASL, 2014

AASLD guideline : post-liver transplantation Treatment-naïve patients with HCV genotype 1 SOF (400 mg/d) + SMV (150 mg/d) ± RBV (escalating dose) for 12-24 weeks (IIb, C) Alternate regimen SOF (400 mg/d) + RBV (escalating dose) ± PEG-IFN for 24 weeks (IIb, C) Treatment-naïve patients with HCV genotype 2 or 3 SOF (400 mg/d) + RBV (escalating dose) for 24 weeks Not recommend Monotherapy with PEG, RBV, or a DAA (III, A) TVR, BOC based regimen (III, A) Treatment naïve patient with decompensated allograft HCV infection SOF (400 mg/d) + wt based RBV (creatinine clearance, Hb) for up to 48 weeks (I, C)

Patients with HCV recurrence after LT Mild progression of recurrence at one year : Liver stiffness <8.7 Kpa (no need for liver biopsy or HVPG) Severe progression of recurrence at one year : Liver stiffness 8.7 Kpa F 2 liver biopsy HVPG 6 mmhg Current therapy Longterm outcome of mild HCV after LT 5yr 10yr Graft loss 3% 10% Cirrhosis 10% 30% Follow-up/ Indivisualize therapy Gambato M, et al. 49 th Annual Meeting of EASL, 2014 ABT-450/r+ABT-267+ABT-333+RBV Simeprevir+ Daclatasvir +RBV Sofosbuvir + Ledipasvir ±RBV Compensated G1 : SOF+SMV ±RBV SOF+SMV ±PEG G2, 3 : SOF+ RBV PEG-IFN+RBV (±TVP/BOC in G1) Incoming therapy (clinical trials with DAA) Decompensated SOF+ RBV Sofosbuvir +Ledipasvir (±RBV) Sofosbuvir +Simeprevir (±RBV) Marino Z, et al. 2014 EASL, PG course

만성콩팥병환자 prevalence of CHC in HD cohorts : 2.6-23% (mean 13.5%) HD patients : screened for HCV at baseline and q 6 months ALT : low or normal 경한콩팥질환 ( 사구체거름률 60 ml/min) 콩팥질환이없는경우와동일 투석전단계의콩팥기능장애 ( 사구체거름률 15-59 ml/min) 감량된페그인터페론알파 (2a 135 ug/wk, 2b 1ug/kg/wk) + 리바비린 200-800 mg/d 투석중인환자 인터페론알파 (2a, 2b 300만 unit, 주3회 ) 감량된페그인터페론알파 (2a 135 ug/wk, 2b 1ug/kg/wk) 1 st generation PIs (BOC, TVR) : high rate of anemia IFN and RBV free therapy HCV treatment before kidney transplantation

PEG-IFN±low dose RBV for treatment-naïve patients with HCV receiving hemodialysis PegIFN -α2a 135ug + RBV 200mg PegIFN -α2a 135ug Genotype 1 n 103 135 (48weeks) SVR 64% 33% Hb <8.5 g/dl 72% 6% Withdrawal (AE) 7% 4% Genotype 2 n 86 86 (24weeks) SVR 74% 44% Hb <8.5 g/dl 70% 8% Withdrawal (AE) 6% 3% Liu CH, et al. Ann Intern Med 2013;159:729 Liu CH, et al. Gut 2014 [Epub ahead of print]

Patients with renal impariment Sofosbuvir : hepatocyte 에서 active form, inactive metabolite renal elimination Simeprevir : liver CYP3A4 에서대사, renal clearance <1%

HIV 중복감염환자 모든 HIV 감염자 : HCV 항체검사 (B1) 혈중 HCV RNA 검사 : HCV 항체양성인경우음성이지만원인불명의간질환 (B1) CD4 양성림프구수 < 200 cells/ul antiretroviral therapy 치료 : 페그인터페론알파 + 체중에따른리바비린용량, 48주 SVR : 1형 14-29%, 2,3형 44-73% didanosine, stavudine, zidovudine은피할것 Acute HCV in HIV patients PEG-IFN + weight based RBV for 24 weeks (RVR+) 48 weeks (RVR-)

SVR for oral DAA to PEG-IFN/RGB for treatment of HCV genotype 1/HIV DAA (oral) PegIFN (SC) RBV (oral) Duration SVR (%, n / N) TVR 750 mg q 8h Alfa-2a 180 ug/wk 1000 or 1200 mg/d BOC 800 mg q 8h Alfa-2b 1.5 ug/kg/wk 600-1400 mg/d 48wks (TVR for initial 12wks) 48wks (BOC for 44wks) 74% (28/38) 75%(271/365) 63% (40/64) 68%(213/311) SMV 150 mg/d Alfa-2a 180 ug/wk 1000 or 1200 mg/d SOF 400 mg/d Alfa-2a 180 ug/wk 1000 or 1200 mg/d SOF 400 mg/d None 1000 or 1200 mg/d 24 or 48 wks based on RVR (SMV for initial 12wks) 79% (42/53) 12 wks (all drugs) 89% (17/19) 24 wks (all drugs) * 12 wks (G2) * 12 wks (G3) 76% (87/114) 88% (23/26) 67% (28/42) Lens S, et al. Semin Liver Dis 2014;34:58

Clinical trials of IFN-free, oral DAA for patients with HCV/HIV NS3/4A Protease inhibitor NS5A inhibitor NS5B nucleotide analogue polymerase inhibitor NS5B nonnucleotide analogue polymerase inhibitor Ribavirin ABT450/ ritonavir Ledipasvir Daclatasvir Sofosbuvir Sofosbuvir ABT333 1000-1200 mg/d MK-5172 MK-8742 1000-1200 mg/d 50 patients with G1, naïve, stable HIV SOF/LDV (400mg/90mg) for 12 weeks SVR4 : 100% Osinusi A, et al. 49 th Annual Meeting of EASL, 2014 Lens S, et al. Semin Liver Dis 2014;34:58

AASLD guideline : HIV/HCV coinfection G 1 : Treatment-naïve and prior PEG/RBV relapsers IFN eligible : SOF+PEG/wt based RBV x 12 wks (I B) IFN ineligible : SOF + RBV x 24 wks (I B) SOF + SMV ± RBV x 12 wks (IIa C) Treatment experienced (PEG/RBV non-responders) SOF+ SMV ± RBV x 12 wks (IIa C) G 2 : SOF + RBV x 12 wks (I B) prior non-responder, cirrhosis - 16 wks G 3 : SOF + RBV x 24 wks (I B) G 4,5,6 : same as HCV monoinfection Allowable antiretroviral therapy SOF : all except didanosine, zidovudine SMV : limited to raltegravir, rilpivirine, maraviroc, enfuvirtide, tenofovir, emtricitabine, lamivudine, abacavir

HBV 중복감염환자 prevalence : 5-20% in HBsAg positive patients 2-10% in HCV positive patients HBsAg/anti-HCV positive patients HCV RNA positive Inactive HBV infection profile Treat as HCV mono-infection. Monitor HBVDNA Active HBV infection Treat with IFN based anti-hcv therapy. HBV response (-) : NUC therapy sequential treatment (anti-hcv first, then anti-hbv) simultaneous treatment : drug interaction IFN telbivudine 피한다.(neuromuscular side effect) BOC : ETV, TDF, ADV, LMV no interaction TVR : TDF (30% 상승 )

경기인천지역 18 명 /758 명 PEG-IFN/RBV : 2.37% 1b : 8 명, 2a/c : 5 명, 2 : 3 명, 1a : 2 명 87.5% 60% Kim YJ, et al. Korean J Hepatol 2011;17:199

정맥주사약물남용자 HCV 항체양성률 48.4-79.2% ( 국내 ) 20-25% of deaths among HCV patient liver disease 1a, 1b, 3a : common, 4d in Europe, 6 in Southeast Asia 메타분석 (2,800 명, 38.2% 약물남용지속 ) 페그인터페론 + 리바비린병합요법 SVR : 44.9%(1 형 ) 70.0%(2, 3 형 ) 약물남용을중단한자 : 현재의표준치료 약물남용지속자 : 환자의치료의지등을분명히평가 약물상호작용 TVR, BOC - methadone 과작용이없으나 heroin 혈중농도증가 SOF : methadone 과작용이없다

치료결정 Chronic Hepatitis C in the Elderly Factors favoring treatment now Few comorbidities Advanced liver fibrosis Extrahepatic manifestations of HCV Factors favoring delaying therapy Comorbidities renal impairment, anemia Minimal liver fibrosis Previous failed therapy Tolerabilty : premature treatment discontinuation, dose reduction > age 60 : 70% : dose reduction of RBV within 12 weeks 30% : stop (vs 15%) anemia, depression, fatigue, flu-like Sx Lower SVR : 46% (>over 60) vs 70% TVR : > age 65 anemia SVR : 50% (pre-cardiac tests, medication Hx) IFN-free therapy (SOF trial, 90%>age 65) no difference in efficacy and tolerability

요약 각환자의개별적상황을충분히고려한다. PEG-IFN/RBV에서새로운 DAA의병합요법 (IFN free regimen) 급성 C형간염 : PEG-IFN 단독으로 12주치료가능 대상성간경변 : 만성 C형간염과동일하게적극적인치료 비대상성간경변 : IFN free DAA regimen을기대 콩팥병환자 : 약제의신장배설관계파악, 신장이식전치료 HIV/HCV 중복감염 : 약물상호작용파악 HBV/HCV 중복감염 : HCV 치료우선, HBV DNA monitoring 정맥주사약물남용자 : 약물상호작용 노년층 : 다른질환여부 ( 신장기능 ), 약물상호관계 새로운 DAA 의 Cost 및 Viral resistance